BPS reports RMB132 million profit in first three quarters, up 58.6% year-on-year

ZC Asia has learnt that on 29 October, A-share listed company BioPure (301080.SZ) formally announced the commencement of its Hong Kong IPO plan. According to the company's announcement, to advance its international strategic layout, the company plans to issue H-shares and list on the Main Board of the Hong Kong Stock Exchange. The company's board has authorised management to commence preparatory work, marking the biotechnology firm's formal entry into a dual-listing strategy across both A-share and H-share markets.

Financial data reveals impressive performance metrics for BioPure. For the first three quarters of 2025, the company achieved operating revenue of RMB613 million, representing a year-on-year increase of 32.3%. Net profit attributable to shareholders reached RMB132 million, rising by 58.6%. Non-recurring net profit attributable to shareholders stood at RMB133 million, up 58.8% year-on-year. Notably, net operating cash flow surged by 99.5% to RMB177 million.

As a specialised enterprise in the biotechnology sector, BioPure primarily focuses on the research, development, production, and sales of biopharmaceuticals. Its products and services are extensively applied across multiple critical stages of pharmaceutical R&D, including early drug discovery and validation, drug screening and optimisation, diagnostic reagent development, as well as preclinical and clinical trials. These cover significant therapeutic areas such as oncology, autoimmune diseases, cardiovascular disorders, and infectious diseases.

The initiation of BioPure's Hong Kong IPO will facilitate the company's expansion into international markets and enhance its participation within the global biopharmaceutical industry chain. Concurrently, the company's robust performance growth provides a solid fundamental underpinning for this overseas listing.

Disclaimer: The content herein is for reference only and does not constitute any form of investment advice. Should any information contained herein prove inaccurate, incomplete, or potentially misleading, please refer to the company's official announcements. Market risks exist; investment requires caution.